Preclinical Evaluation of the Tumorigenic and Immunomodulatory Properties of Human Bone Marrow Mesenchymal Stromal Cell Populations with Clonal Trisomy 5

Table 2

Tumor incidence, overall survival, and adverse signs in nude mice after 185 days of subcutaneous injection of MSC or tumor cells. Animals Survival after cell inoculation (p =0.2247).

Cell sample injected	Cell description	Frequency of tumor-bearing animals/total animals evaluated	Survival at day 185 post-injection	Adverse clinical signs
T5-50	Human MSC cells harboring trisomy 5	0/3	100%	None
T5-53	Human MSC cells harboring trisomy 5	0/3	67%	1 animal with reduced mobility
M10	Human euploid MSC	0/3	100%	None
M12	Human euploid MSC	0/3	67%	1 animal with consistent weight loss
USP7	Human ATRT tumor cells	2/3	33%	2 tumor-bearing animals with reduced activity and excessive weight loss